Dermapharm publishes transcript of H1 2026 results call

Reuters2026/08/27 07:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Dermapharm published an H1 2026 results call transcript attended by CFO Christof Dreibholz, CMO Andreas Eberhorn, and moderator Britta Hamberger.
CFO confirmed FY26 outlook; no material impact expected from Germany’s Financial Stabilization Act in the rest of 2026.
Q2 share buyback of 4,300,000 shares for EUR 181 million cut equity ratio to about 24%; leverage rose to 3x adjusted EBITDA.
Mucos purchase-price allocation currently implies about EUR 24 million badwill; release booked as non-cash income, removed from adjusted EBITDA.
BaFin is reviewing valuation and related-party disclosure tied to a Dutch cannabis receivable; management maintained prior-year accounting was appropriate.
New 2026 market data triggered a EUR 30 million impairment of the FYTA-related receivable; valuation to be reassessed each balance-sheet date.
CFO cited annual free cash flow of about EUR 180-190 million; planned EUR 60 million debt reduction, about EUR 40 million interest cost.
Branded pharmaceuticals organic net sales growth ran 4%-5%, split roughly evenly between domestic and international markets.
Arkopharma ran ahead of budget; CMO pointed to recent category launches and three months of above-market growth in France supporting H2 confidence.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermapharm Holding SE published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Dermapharm publishes transcript of H1 2026 results call

You may also like

Crypto prices